Revenue (Tables)

3 Months Ended

Mar. 31, 2024

Revenue [abstract]

Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss

Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss in the following amounts:

	Three Months Ended March 31,
	2024		2023
	(EUR’000)
Revenue
Sale of commercial products		66,499		31,551
Rendering of services		4,624		1,170
Sale of clinical supply		1		254
Licenses		24,770		614
Total revenue		95,894		33,589
Attributable to
Commercial customers		66,499		31,551
Collaboration partners and license agreements		29,395		2,038
Total revenue		95,894		33,589
Specified by timing of recognition
Recognized over time		4,624		1,170
Recognized at a point in time		91,270		32,419
Total revenue		95,894		33,589
Specified per geographical location
Europe		1,567		—
North America		92,681		33,070
Asia		1,646		519
Total revenue		95,894		33,589